Generic drug: valganciclovir hydrochloride
Brand name: Valcyte
What is Valcyte (valganciclovir hydrochloride), and how does it work?
Valcyte (valganciclovir hydrochloride) is a prescription antiviral medicine used to treat Cytomegalovirus (CMV) Retinitis in patients with acquired immunodeficiency syndrome (AIDS) and to prevent CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]).
What are the side effects of Valcyte?
HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS
- Hematologic Toxicity: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure including aplastic anemia have been reported in patients treated with Valcyte.
- Impairment of Fertility: Based on animal data and limited human data, Valcyte may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females.
- Fetal Toxicity: Based on animal data, Valcyte has the potential to cause birth defects in humans.
- Mutagenesis and Carcinogenesis: Based on animal data, Valcyte has the potential to cause cancers in humans.
The most common side effects of Valcyte in adults include:
- shaky movements (tremors)
- low white cell, red cell and platelet cell counts in blood tests
- urinary tract infection
The most common side effects of Valcyte in children include:
- upper respiratory tract infection
- urinary tract infection
- low white blood cell counts in blood tests
These are not all the possible side effects of Valcyte.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is the dosage for Valcyte?
General Dosing Information
- Adult patients should use Valcyte tablets, not Valcyte for oral solution.
- Valcyte for oral solution and tablets should be taken with food.
- Valcyte for oral solution (50 mg/mL) must be prepared by the pharmacist prior to dispensing to the patient.
Recommended Dosage In Adult Patients With Normal Renal Function
For dosage recommendations in adult patients with renal impairment.
Treatment Of CMV Retinitis
- Induction: The recommended dosage is 900 mg (two 450 mg tablets) taken orally twice a day for 21 days.
- Maintenance: Following induction treatment, or in adult patients with inactive CMV retinitis, the recommended dosage is 900 mg (two 450 mg tablets) taken orally once a day.
Prevention Of CMV Disease
- For adult patients who have received a heart or kidney-pancreas transplant, the recommended dosage is 900 mg (two 450 mg tablets) taken orally once a day starting within 10 days of transplantation until 100 days post-transplantation.
- For adult patients who have received a kidney transplant, the recommended dosage is 900 mg (two 450 mg tablets) taken orally once a day starting within 10 days of transplantation until 200 days post-transplantation.
Recommended Dosage In Pediatric Patients
Prevention Of CMV Disease In Pediatric Kidney Transplant Patients
- For pediatric kidney transplant patients 4 months to 16 years of age, the recommended once daily mg dose (7 x BSA x CrCl) should start within 10 days of post-transplantation until 200 days post-transplantation.
Prevention Of CMV Disease In Pediatric Heart Transplant Patients:
- For pediatric heart transplant patients 1 month to 16 years of age, the recommended once daily mg dose (7 x BSA x CrCl) should start within 10 days of transplantation until 100 days post-transplantation.
- The recommended once daily dosage of Valcyte is based on body surface area (BSA) and creatinine clearance (CrCl) derived from a modified Schwartz formula, and is calculated using the equation below:
- Pediatric Dose (mg) = 7 x BSA x CrCl (calculated using a modified Schwartz formula). If the calculated Schwartz creatinine clearance exceeds 150 mL/min/1.73m², then a maximum value of 150 mL/min/1.73m² should be used in the equation. The k values used in the modified Schwartz formula are based on pediatric patient age, as shown in Table 1.
Table 1 : k Values According to Pediatric Patient Age*
|k value||Pediatric Patient Age|
|0.33||Infants less than 1 year of age with low birth weight for gestational age|
|0.45||Infants less than 1 year of age with birth weight appropriate for gestational age|
|0.45||Children aged 1 to less than 2 years|
|0.55||Boys aged 2 to less than 13 years Girls aged 2 to less than 16 years|
|0.7||Boys aged 13 to 16 years|
|*The k values provided are based on the Jaffe method of measuring serum creatinine, and may require correction when enzymatic methods are used1.|
- Monitor serum creatinine levels regularly and consider changes in height and body weight and adapt the dose as appropriate during prophylaxis period.
- All calculated doses should be rounded to the nearest 25 mg increment for the actual deliverable dose.
- The oral dispenser is graduated in 0.5 mL increments. A 50 mg dose is equivalent to 1 mL.
- If the calculated dose exceeds 900 mg, a maximum dose of 900 mg should be administered. Valcyte for oral solution is the preferred formulation since it provides the ability to administer a dose calculated according to the formula above; however, Valcyte tablets may be used if the calculated doses are within 10% of available tablet strength (450 mg). For example, if the calculated dose is between 405 mg and 495 mg, one 450 mg tablet may be taken.
- Before prescribing Valcyte tablets, pediatric patients should be assessed for the ability to swallow tablets.
Preparation Of Valcyte For Oral Solution
Wearing disposable gloves is recommended during reconstitution and when wiping the outer surface of the bottle/cap and the table after reconstitution. Prior to dispensing to the patient, Valcyte for oral solution must be prepared by the pharmacist as follows:
- Measure 91 mL of purified water in a graduated cylinder.
- Shake the Valcyte bottle to loosen the powder. Remove the child resistant bottle cap and add approximately half the total amount of water for constitution to the bottle and shake the closed bottle well for about 1 minute. Add the remainder of water and shake the closed bottle well for about 1 minute. This prepared solution contains 50 mg of valganciclovir free base per 1 mL.
- Remove the child resistant bottle cap and push the bottle adapter into the neck of the bottle.
- Close bottle with child resistant bottle cap tightly. This will assure the proper seating of the bottle adapter in the bottle and child resistant status of the cap.
- Store constituted oral solution under refrigeration at 2°C to 8°C (36°F to 46°F) for no longer than 49 days. Do not freeze.
- Write the discard date of the constituted oral solution on the bottle label.
The patient package insert, which includes the dosing instructions for patients, and 2 oral dispensers should be dispensed to the patient.
Dosage Recommendation For Adult Patients With Renal Impairment
Serum creatinine levels or estimated creatinine clearance should be monitored regularly during treatment. Dosage recommendations for adult patients with reduced renal function are provided in Table 2. For adult patients on hemodialysis Â (CrCl less than 10 mL/min), a dose recommendation for Valcyte cannot be given.
Table 2 : Dosage Recommendations for Adult Patients with Impaired Renal Function
|Valcyte 450 mg Tablets|
|CrCl* (mL/min)||Induction Dose||Maintenance/ Prevention Dose|
|≥ 60||900 mg twice daily||900 mg once daily|
|40 - 59||450 mg twice daily||450 mg once daily|
|25 - 39||450 mg once daily||450 mg every 2 days|
|10 - 24||450 mg every 2 days||450 mg twice weekly|
|< 10 (on hemodialysis)||not recommended||not recommended|
|*An estimated creatinine clearance in adults is calculated from serum creatinine by the following formulas:|
|For males:||(weight in kg) x (140 – age)
(72) x serum creatinine (mg/100 mL)
|For females:||0.85 x male value|
Dosing in pediatric patients with renal impairment can be done using the recommended equations because CrCl is a component in the calculation.
Handling And Disposal
Caution should be exercised in the handling of Valcyte tablets and Valcyte for oral solution. Tablets should not be broken or crushed. Because valganciclovir is considered a potential teratogen and carcinogen in humans, caution should be observed in handling broken tablets, the powder for oral solution, and the constituted oral solution. Avoid direct contact with broken or crushed tablets, the powder for oral solution, and the constituted oral solution with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, and rinse eyes thoroughly with plain water.
Handle and dispose Valcyte according to guidelines for antineoplastic drugs because ganciclovir shares some of the properties of antitumor agents (i.e., carcinogenicity and mutagenicity).
What drugs interact with Valcyte?
- In vivo drug-drug interaction studies were not conducted with valganciclovir. However, because valganciclovir is rapidly and extensively converted to ganciclovir, drug-drug interactions associated with ganciclovir will be expected for Valcyte.
- Drug-drug interaction studies with ganciclovir were conducted in patients with normal renal function.
- Following concomitant administration of Valcyte and other renally excreted drugs, patients with impaired renal function may have increased concentrations of ganciclovir and the coadministered drug. Therefore, these patients should be closely monitored for toxicity of ganciclovir and the coadministered drug.
- Established and other potentially significant drug interactions conducted with ganciclovir are listed in Table 9.
Table 9 : Established and Other Potentially Significant Drug Interactions with Ganciclovir
|Name of the Concomitant Drug||Change in the Concentration of Ganciclovir or Concomitant Drug||Clinical Comment|
|Imipenem-cilastatin||Unknown||Coadministration with imipenem-cilastatin is not recommended because generalized seizures have been reported in patients who received ganciclovir and imipenem-cilastatin.|
|Cyclosporine or amphotericin B||Unknown||Monitor renal function when Valcyte is coadministered with cyclosporine or amphotericin B because of potential increase in serum creatinine.|
|Mycophenolate mofetil (MMF)||↔Ganciclovir (in patients with normal renal function)|
↔MMF (in patients with normal renal function)
|Based on increased risk, patients should be monitored for hematological and renal toxicity.|
|Other drugs associated with myelosuppression or nephrotoxicity (e.g., adriamycin, dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine, and zidovudine)||Unknown||Because of potential for higher toxicity, coadministration with Valcyte should be considered only if the potential benefits are judged to outweigh the risks.|
|Didanosine||↔ Ganciclovir ↑Didanosine||Patients should be closely monitored for didanosine toxicity (e.g., pancreatitis)|
|Probenecid||↑Ganciclovir||Valcyte dose may need to be reduced. Monitor for evidence of ganciclovir toxicity.|
Latest HIV News
- PrEP HIV Prevention Pills to Be Free for Insured
- People With HIV Have Near-Normal Life Expectancy
- People With HIV Have Much Higher Risk for Suicide
- Living With HIV Raises Sudden Cardiac Death Risk
- Disappointment and Hope From HIV Prevention Trials
- Want More News? Sign Up for MedicineNet Newsletters!
Daily Health News
Is Valcyte safe to use while pregnant or breastfeeding?
- After oral administration, valganciclovir (prodrug) is converted to ganciclovir (active drug) and, therefore, Valcyte is expected to have reproductive toxicity effects similar to ganciclovir.
- No data are available regarding the presence of valganciclovir (prodrug) or ganciclovir (active drug) in human milk, the effects on the breastfed infant, or the effects on milk production.
Valcyte (valganciclovir hydrochloride) is a prescription antiviral medicine used to treat Cytomegalovirus (CMV) Retinitis in patients with acquired immunodeficiency syndrome (AIDS) and to prevent CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]). Serious side effects of Valcyte include hematologic toxicity, impairment of fertility, fetal toxicity, and mutagenesis and carcinogenesis.
Multimedia: Slideshows, Images & Quizzes
HIV AIDS: Myths and Facts
What is HIV versus AIDS? What are the symptoms of HIV? Is there an HIV cure? Discover myths and facts about living with HIV/AIDS....
A Timeline of the HIV/AIDS Pandemic
Get a historical overview of the HIV/AIDS pandemic from human contraction to the present through this slideshow of pictures.
What Are HIV & AIDS? Symptoms, Treatment, and Prevention
HIV, or human immunodeficiency virus, causes acquired immunodeficiency syndrome, or AIDS. Learn about HIV positive, being HIV...
HIV & AIDS Quiz: HIV Testing & Symptoms
Now, more than ever, you should know about HIV/AIDS, especially its causes, symptoms treatments, and complications. Take the...
Picture of HIV/AIDS
Acronym for the Human Immunodeficiency Virus, the cause of AIDS (acquired immunodeficiency syndrome). See a picture of HIV/AIDS...
Picture of HIV Lipodystrophy
HIV lipodystrophy describes a constellation of changes in subcutaneous and visceral fat distribution in patients on...
Picture of HIV Lipodystrophy Treatment
HIV lipodystrophy describes a constellation of changes in subcutaneous and visceral fat distribution in patients on...
Related Disease Conditions
HIV Early Signs and Stages
Human immunodeficiency virus or HIV, destroys important cells that fight disease and infection, which weakens a person's immune system. Some people with HIV don’t have any signs or symptoms. Early signs and symptoms of HIV infection include mononucleosis-like or flu-like symptoms, which include body aches, fever, and headache. Signs and symptoms begin around seven or eight years after HIV infection, which include weight loss, loss of energy and appetite, and swollen lymph nodes. There are 3 stages of HIV.
HIV and AIDS
Second Source article from WebMD
AIDS (Acquired Immunodeficiency Syndrome)
AIDS is the advanced stage of HIV infection. Symptoms and signs of AIDS include pneumonia due to Pneumocystis jiroveci, tuberculosis, toxoplasmosis, seizures, weakness, meningitis, yeast infection of the esophagus, and Kaposi's sarcoma. Anti-retroviral therapy (HAART) is used in the treatment of AIDS.
Can HIV be Cured Naturally?
HIV stands for human immunodeficiency virus. If someone has HIV it means that they have been diagnosed with the HIV infection. AIDS (acquired immune deficiency syndrome); however, is the most advanced or final stage of the HIV infection. It is important to get tested for HIV in the early stages of infection to minimize the damage to the immune system. Successful treatment aims to reduce HIV load to a level that is harmless to the body.
HIV vs. AIDS
Human immunodeficiency virus causes HIV infection. Acquired immunodeficiency syndrome (AIDS) is a condition that results after HIV has extensively damaged a person's immune system. Risk factors for HIV and AIDS include use of contaminated needles or syringes, unprotected sex, STDs, receiving a blood transfusion prior to 1985 in the United States, having many sex partners, and transmission from a mother to her child.
HIV/AIDS Testing: Diagnosis and Monitoring
HIV/AIDS diagnosis and monitoring have come a long way from the days when a diagnosis was a death sentence. Crucial parts of the effective treatment regimens developed in the last 40 years are consistent monitoring of the viral load (the amount of virus in the blood), and the immune cell count, which function as biological markers of the disease’s progression. Doctors also must test for drug resistance.
HIV/AIDS Facts: What Is HIV?
HIV (human immunodeficiency virus) is the precursor infection to AIDS (acquired immunodeficiency syndrome). HIV is transmitted through blood and genital secretions; most people get it through sexual contact or sharing needles for illegal IV drug use. HIV can be controlled by a strict drug regimen, but left unchecked, it leads to AIDS. In AIDS, the immune system collapses and the body falls prey to secondary, opportunistic infections and cancers that typically kill the person.
HIV/AIDS Infection Transmission and Prevention
HIV (human immunodeficiency virus) is spread through contact with genital fluids or blood of an infected person. The spread of HIV can occur when these secretions come in contact with tissues such as those lining the vagina, anal area, mouth, eyes (the mucus membranes), or with a break in the skin, such as from a cut or puncture by a needle.
HIV Medications List and Drug Charts
The ultimate goal of HIV treatment is getting the viral load down below detectable levels. As long as those viral load and antibody levels are below a proscribed range, people with HIV can stave off AIDS and other serious symptoms. Antiviral treatment options usually include combinations of two NRTIs, often referred to as "nucs," and a third drug, typically being a boosted protease inhibitor, a NNRTI, often called "non-nucs," and integrase strand transfer inhibitors.
When should you start HIV medication?
Nearly everyone who is infected with HIV (human immunodeficiency virus) should start antiviral medication therapy as soon as they are diagnosed. Older guidelines recommended delaying treatment to help reduce the potential for drug side effects and viral resistance to treatment. Current thinking theorizes that early treatment may preserve more of the body's immune function.
What Are the Side Effects of HIV Medications?
It’s important to know the potential side effects of all the drugs you take to control your HIV infection, as well as potential drug interactions. All of the NNRTIs (nonnucleoside analogue reverse transcriptase inhibitors), for example, are associated with important drug-drug interactions so they must be used with caution in patients on other medications. Learn more about the side effects of the drugs in standard treatment regimens.
HIV Life Expectancy and Long-term Outlook
With early diagnosis and proper treatment, people with HIV can live a healthy and long life. There is no generalized definitive period for which a person with HIV can live.
Treatment & Diagnosis
- HIV-AIDS FAQs
- HIV Treatment, Medications, and Prevention
- HIV Urine Test Approved
- HIV Treatment - To Interrupt or Not
- Unprotected Sex Between HIV-Infected Partners: What's the Harm?
- HIV Transmission and Progression to AIDS Continues
- Physical and Biochemical Changes in HIV Disease
- Babies On The Breast Of HIV Moms
- Generic AIDS Drug Effective - And Now?
- How Long Should You Wait to Get an HIV Test?
- What Liver Problems Does HIV Cause?
- Can HIV Cause Kaposi's Sarcoma?
- Do You Need Antiretroviral Therapy for HIV with No Symptoms?
- Does HIV Cause Colorectal Cancer?
- Does Anti-Retroviral Therapy for HIV Cause Diabetes?
- Does Circumcision Prevent HIV and AIDS?
- HIV Infection Facts, History, Causes, and Risk Factors
- HIV Tests, Symptoms, Signs, and Stages of Infection
- Baby "Cured" of HIV Infection
Medications & Supplements
- Valtrex (valacyclovir) vs. Valcyte (valganciclovir)
- How Effective Is ART for HIV Infection?
- What Are NNRTIs In Antiretroviral Therapy for HIV Infection?
- What Are NRTIs in Antiretroviral Therapy For HIV Infection?
- How Do Protease Inhibitors Work in Antiretroviral Therapy for HIV Infection?
- valganciclovir- oral, Valcyte
- What ART Drugs Prevent HIV Entry into the Human Immune Cell?
- How Do Integrase Strand-Transfer Inhibitors Work in Antiretroviral Therapy for HIV Infection?
- What Are the Single-Tablet ART Regimens for HIV Infection?
Prevention & Wellness
Subscribe to MedicineNet's General Health Newsletter
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.